Focus on Immunizations

Back to articles

Children’s Pneumococcal Vaccine Mixes Clinical, Socioeconomic Factors

KEY POINT

Wyeth Lederle Vaccines’ new product, Prevnar, has been approved by FDA for use in preventing infections of the seven most common strains of Streptococcus pneumoniae in children less than 6 years old. Primarily because of the cost of the vaccine, FDA and CDC are recommending use in all infants up to age 23 months and in certain high-risk socioeconomic groups of children ages 24 to 59 months.